BiomX Insider Shake‑Ups: Director Converts Preferred Shares to Common, Sells for $5 Each in Quick Liquidity Move Ahead of Dilution Event
Insider trades at BiomX reveal a tactical shift: converting Series Y preferred to common and selling at $5 each before dilution, showing short‑term liquidity gains while executives remain bullish on phage therapy prospects.
3 minutes to read